EA202091262A1 - Пиперидиновые модуляторы рецепторов cxcr7 - Google Patents

Пиперидиновые модуляторы рецепторов cxcr7

Info

Publication number
EA202091262A1
EA202091262A1 EA202091262A EA202091262A EA202091262A1 EA 202091262 A1 EA202091262 A1 EA 202091262A1 EA 202091262 A EA202091262 A EA 202091262A EA 202091262 A EA202091262 A EA 202091262A EA 202091262 A1 EA202091262 A1 EA 202091262A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cxcr7
piperidine
receptor modulators
formula
modulators
Prior art date
Application number
EA202091262A
Other languages
English (en)
Inventor
Хамед Айссауи
Филипп Герри
Франсуа Леамбр
Жюльен Потье
Летиция Пузоль
Сильвия Рихард-Бильдштайн
Шугуан Юань
Original Assignee
Идорсия Фармасьютиклз Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Идорсия Фармасьютиклз Лтд filed Critical Идорсия Фармасьютиклз Лтд
Publication of EA202091262A1 publication Critical patent/EA202091262A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Настоящее изобретение относится к пиперидиновым производным формулы (I)где Ar, Ar, R, R, Rи Rимеют значения, указанные в описании, к их получению, к их фармацевтически приемлемым солям и к их применению в качестве фармацевтических препаратов, к фармацевтическим композициям, которые содержат одно или несколько соединений формулы (I), и в особенности к их применению в качестве модуляторов рецепторов CXCR7.
EA202091262A 2016-07-28 2017-07-27 Пиперидиновые модуляторы рецепторов cxcr7 EA202091262A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2016068052 2016-07-28

Publications (1)

Publication Number Publication Date
EA202091262A1 true EA202091262A1 (ru) 2020-08-13

Family

ID=59656027

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201990388A EA037507B1 (ru) 2016-07-28 2017-07-27 Пиперидиновые модуляторы рецепторов cxcr7
EA202091262A EA202091262A1 (ru) 2016-07-28 2017-07-27 Пиперидиновые модуляторы рецепторов cxcr7

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201990388A EA037507B1 (ru) 2016-07-28 2017-07-27 Пиперидиновые модуляторы рецепторов cxcr7

Country Status (32)

Country Link
US (2) US10752620B2 (ru)
EP (2) EP3798217B1 (ru)
JP (2) JP6655754B2 (ru)
KR (2) KR102497091B1 (ru)
CN (2) CN110563717B (ru)
AR (2) AR109180A1 (ru)
AU (2) AU2017302079B2 (ru)
BR (1) BR112019001551A2 (ru)
CA (1) CA3032017C (ru)
CL (2) CL2019000169A1 (ru)
CY (1) CY1125016T1 (ru)
DK (2) DK3490986T3 (ru)
EA (2) EA037507B1 (ru)
ES (2) ES2905755T3 (ru)
FI (1) FI3798217T3 (ru)
HR (2) HRP20230313T1 (ru)
HU (2) HUE057315T2 (ru)
IL (2) IL264424B (ru)
LT (2) LT3798217T (ru)
MA (2) MA54653B1 (ru)
MX (2) MX2019001042A (ru)
MY (1) MY198113A (ru)
NZ (1) NZ751006A (ru)
PH (1) PH12019500188A1 (ru)
PL (2) PL3798217T3 (ru)
PT (2) PT3798217T (ru)
RS (2) RS64130B1 (ru)
SG (2) SG11201900633XA (ru)
SI (2) SI3490986T1 (ru)
TW (3) TWI691497B (ru)
WO (1) WO2018019929A1 (ru)
ZA (1) ZA201901256B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019212888B8 (en) * 2018-01-26 2024-01-04 Idorsia Pharmaceuticals Ltd Crystalline forms of the CXCR7 receptor antagonist (3s,4s)-1- cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide
IL292529A (en) 2019-10-31 2022-06-01 Idorsia Pharmaceuticals Ltd Combination of cxcr7 antagonist with s1p1 receptor modulator
WO2023012044A1 (en) 2021-08-02 2023-02-09 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
KR102524669B1 (ko) * 2021-10-01 2023-04-21 주식회사 넥스트젠바이오사이언스 신규한 피페리딘 유도체 및 이를 포함하는 오토탁신 저해용 약학 조성물
WO2023110871A1 (en) 2021-12-17 2023-06-22 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
EP4238970A1 (en) 2022-03-03 2023-09-06 InterAx Biotech AG Modulators of ackr3 and uses thereof
CN115403510B (zh) * 2022-08-11 2023-04-25 南方医科大学 一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途
WO2024105104A1 (en) 2022-11-16 2024-05-23 Syngenta Crop Protection Ag Microbiocidal tetrahydroisoquinoline derivatives

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102324A1 (en) * 2002-02-28 2004-05-27 Annis Gary David Heterocyclic diamide invertebrate pest control agents
HU230612B1 (hu) 2002-11-27 2017-04-28 Incyte Corporation Kemokin receptorokat módosító hatású 3-aminopirrolidin-származékok
TW200526626A (en) * 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
EP1670739A4 (en) 2003-10-08 2007-08-08 Bristol Myers Squibb Co CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS
KR101422432B1 (ko) 2005-02-18 2014-07-22 아스트라제네카 아베 항균성 피페리딘 유도체
JP5785089B2 (ja) * 2008-11-04 2015-09-24 ケモセントリックス，インコーポレイティド Ｃｘｃｒ７の調節因子
WO2012168315A1 (en) 2011-06-09 2012-12-13 Boehringer Ingelheim International Gmbh Substituted piperidines as gpr119 modulators for the treatment of metabolic disorders
WO2013084241A1 (en) * 2011-12-09 2013-06-13 Cadila Healthcare Limited Compounds as inhibitors of renin
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
BR112015012366A8 (pt) * 2012-11-29 2019-10-01 Chemocentryx Inc antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido
US9920010B2 (en) 2013-05-30 2018-03-20 Idorsia Pharmaceuticals Ltd CXCR7 receptor modulators
AU2014315457B2 (en) 2013-09-04 2018-05-10 Bristol-Myers Squibb Company Compounds useful as immunomodulators
CA2922607C (en) 2013-09-06 2022-08-30 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
EP3193605A4 (en) * 2014-09-10 2018-04-18 Epizyme, Inc. Substituted piperidine compounds
CA2963447A1 (en) 2014-12-01 2016-06-09 Actelion Pharmaceuticals Ltd Cxcr7 receptor modulators
AU2019212888B8 (en) 2018-01-26 2024-01-04 Idorsia Pharmaceuticals Ltd Crystalline forms of the CXCR7 receptor antagonist (3s,4s)-1- cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide

Also Published As

Publication number Publication date
IL282942B (en) 2022-01-01
MX2019001042A (es) 2019-06-10
US10752620B2 (en) 2020-08-25
LT3798217T (lt) 2023-05-25
MX2021004000A (es) 2021-06-23
JP6655754B2 (ja) 2020-02-26
TW201922738A (zh) 2019-06-16
ES2954152T3 (es) 2023-11-20
CL2019000169A1 (es) 2019-06-21
CN110563717B (zh) 2022-08-09
KR102497095B1 (ko) 2023-02-06
RS62855B1 (sr) 2022-02-28
AU2017302079B2 (en) 2021-07-22
EP3798217B1 (en) 2023-02-22
MA54653A (fr) 2021-12-29
EA037507B1 (ru) 2021-04-06
HRP20211988T1 (hr) 2022-03-18
CA3032017C (en) 2023-04-18
MA45782A (fr) 2019-06-05
DK3798217T3 (da) 2023-05-22
IL264424B (en) 2021-08-31
EP3798217A1 (en) 2021-03-31
PL3490986T3 (pl) 2022-04-04
JP2019142874A (ja) 2019-08-29
PH12019500188A1 (en) 2019-10-21
CN110563717A (zh) 2019-12-13
EP3490986A1 (en) 2019-06-05
US20190169180A1 (en) 2019-06-06
MA54653B1 (fr) 2023-04-28
PT3490986T (pt) 2022-02-01
JP6655742B2 (ja) 2020-02-26
TWI683812B (zh) 2020-02-01
AR115662A2 (es) 2021-02-10
CN109563085A (zh) 2019-04-02
TW201932454A (zh) 2019-08-16
TWI691497B (zh) 2020-04-21
AR109180A1 (es) 2018-11-07
MA45782B1 (fr) 2021-12-31
IL264424A (en) 2019-02-28
AU2020204578A1 (en) 2020-07-30
TWI691494B (zh) 2020-04-21
JP2019525927A (ja) 2019-09-12
BR112019001551A2 (pt) 2019-05-14
LT3490986T (lt) 2022-02-10
TW201806940A (zh) 2018-03-01
HUE057315T2 (hu) 2022-04-28
WO2018019929A1 (en) 2018-02-01
US11306078B2 (en) 2022-04-19
US20200385373A1 (en) 2020-12-10
NZ751006A (en) 2021-07-30
CA3032017A1 (en) 2018-02-01
ES2905755T3 (es) 2022-04-12
DK3490986T3 (da) 2022-03-07
ZA201901256B (en) 2021-08-25
EP3490986B1 (en) 2021-11-24
SI3798217T1 (sl) 2023-05-31
HRP20230313T1 (hr) 2023-05-12
EA201990388A1 (ru) 2019-08-30
FI3798217T3 (fi) 2023-05-03
SI3490986T1 (sl) 2022-02-28
KR20200092420A (ko) 2020-08-03
KR102497091B1 (ko) 2023-02-06
AU2020204578B2 (en) 2022-03-10
KR20190034620A (ko) 2019-04-02
PT3798217T (pt) 2023-05-23
MY198113A (en) 2023-08-03
HUE062019T2 (hu) 2023-09-28
SG10201906942PA (en) 2019-09-27
AU2017302079A1 (en) 2019-03-21
SG11201900633XA (en) 2019-02-27
CN109563085B (zh) 2022-08-09
RS64130B1 (sr) 2023-05-31
IL282942A (en) 2021-06-30
CL2019003281A1 (es) 2020-05-04
CY1125016T1 (el) 2023-03-24
PL3798217T3 (pl) 2023-06-12

Similar Documents

Publication Publication Date Title
EA202091262A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA201401351A1 (ru) Производные бензимидазол-пролина
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201891179A1 (ru) N-замещенные индольные производные в качестве модуляторов pge2 рецепторов
EA201992679A1 (ru) N-замещенные индольные производные
EA201501163A1 (ru) Модуляторы рецептора cxcr7
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
TR201904639T4 (tr) Muskarinik M1 reseptörü pozitif allosterik modülatörler.
EA201600394A1 (ru) Трициклические соединения пиперидина
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона
PH12016501625A1 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
CY1123185T1 (el) Παραγωγα ινδολιου
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
EA201600166A1 (ru) Производные пиперидина и азепина как модуляторы рецептора прокинетицина
EA201590886A1 (ru) Замещенные производные индола
EA202090397A1 (ru) Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht-рецептора
UA112586C2 (uk) Похідні бензімідазолпроліну